GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
<p dir="ltr">Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as groundbreaking therapeutic agents in managing a spectrum of <u>metabolic disorders</u>, demonstrating remarkable efficacy across multiple organ systems and disease states. These compounds ar...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513533602955264 |
|---|---|
| author | Abdelilah Arredouani (10914455) |
| author_facet | Abdelilah Arredouani (10914455) |
| author_role | author |
| dc.creator.none.fl_str_mv | Abdelilah Arredouani (10914455) |
| dc.date.none.fl_str_mv | 2025-02-27T12:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.pharmthera.2025.108824 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/GLP-1_receptor_agonists_are_we_witnessing_the_emergence_of_a_paradigm_shift_for_neuro-cardio-metabolic_disorders_/30455630 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences GLP-1 GLP-1 receptor GLP-1 receptor agonists Diabetes Obesity MASLD Neurodegenerative diseases |
| dc.title.none.fl_str_mv | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as groundbreaking therapeutic agents in managing a spectrum of <u>metabolic disorders</u>, demonstrating remarkable efficacy across multiple organ systems and disease states. These compounds are not only well-established in the treatment of <u>type 2 diabetes</u> (T2D) and obesity—conditions for which they have received widespread approval—but also exhibit promising potential in addressing cardiovascular disease (CVD) and Metabolic dysfunction-associated steatotic liver disease (MASLD). Recent investigations have begun to illuminate the utility of GLP-1RAs in the management of <u>type 1 </u>diabetes (T1D), as well as neurodegenerative disorders such as Alzheimer's and <u>Parkinson's disease</u> and various behavioral disorders. A plethora of <u>clinical trials </u>have consistently validated the capacity of GLP-1RAs to improve glycemic control, promote weight loss, and mitigate cardiovascular risk factors in individuals with T2D and obesity. While their application in T1D remains limited due to safety concerns—particularly regarding the risks of hypoglycemia and hyperglycemic ketoacidosis—emerging data suggest that GLP-1RAs may offer hepatoprotective benefits, potentially reducing liver fat content and decelerating the progression of MASLD. The <u>neuroprotective </u>attributes of GLP-1 RAs have garnered significant interest, with research indicating their potential to alleviate cognitive decline associated with <u>neurodegenerative diseases</u>. Furthermore, preliminary findings highlight the role of GLP-1 RAs in addressing behavioral disorders, emphasizing their extensive therapeutic promise. This comprehensive review synthesizes the current evidence supporting the diverse therapeutic applications of GLP-1RAs, positioning them as “magic drug” therapies for metabolic and <u>neurological disorders</u>. As ongoing research continues to explore innovative applications and combinations of GLP-1RAs, the landscape of disease management in metabolic and neurological contexts is poised for transformative advancements. This review will also critically assess safety considerations and underscore the need for personalized treatment strategies to optimize patient outcomes in these complex and often comorbid conditions.</p><h2>Other Information</h2><p dir="ltr">Published in: Pharmacology & Therapeutics<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.pharmthera.2025.108824" target="_blank">https://dx.doi.org/10.1016/j.pharmthera.2025.108824</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_0bb69b97434e2e08a4f097e4cf564542 |
| identifier_str_mv | 10.1016/j.pharmthera.2025.108824 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30455630 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?Abdelilah Arredouani (10914455)Biomedical and clinical sciencesMedical biochemistry and metabolomicsNeurosciencesPharmacology and pharmaceutical sciencesGLP-1GLP-1 receptorGLP-1 receptor agonistsDiabetesObesityMASLDNeurodegenerative diseases<p dir="ltr">Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as groundbreaking therapeutic agents in managing a spectrum of <u>metabolic disorders</u>, demonstrating remarkable efficacy across multiple organ systems and disease states. These compounds are not only well-established in the treatment of <u>type 2 diabetes</u> (T2D) and obesity—conditions for which they have received widespread approval—but also exhibit promising potential in addressing cardiovascular disease (CVD) and Metabolic dysfunction-associated steatotic liver disease (MASLD). Recent investigations have begun to illuminate the utility of GLP-1RAs in the management of <u>type 1 </u>diabetes (T1D), as well as neurodegenerative disorders such as Alzheimer's and <u>Parkinson's disease</u> and various behavioral disorders. A plethora of <u>clinical trials </u>have consistently validated the capacity of GLP-1RAs to improve glycemic control, promote weight loss, and mitigate cardiovascular risk factors in individuals with T2D and obesity. While their application in T1D remains limited due to safety concerns—particularly regarding the risks of hypoglycemia and hyperglycemic ketoacidosis—emerging data suggest that GLP-1RAs may offer hepatoprotective benefits, potentially reducing liver fat content and decelerating the progression of MASLD. The <u>neuroprotective </u>attributes of GLP-1 RAs have garnered significant interest, with research indicating their potential to alleviate cognitive decline associated with <u>neurodegenerative diseases</u>. Furthermore, preliminary findings highlight the role of GLP-1 RAs in addressing behavioral disorders, emphasizing their extensive therapeutic promise. This comprehensive review synthesizes the current evidence supporting the diverse therapeutic applications of GLP-1RAs, positioning them as “magic drug” therapies for metabolic and <u>neurological disorders</u>. As ongoing research continues to explore innovative applications and combinations of GLP-1RAs, the landscape of disease management in metabolic and neurological contexts is poised for transformative advancements. This review will also critically assess safety considerations and underscore the need for personalized treatment strategies to optimize patient outcomes in these complex and often comorbid conditions.</p><h2>Other Information</h2><p dir="ltr">Published in: Pharmacology & Therapeutics<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.pharmthera.2025.108824" target="_blank">https://dx.doi.org/10.1016/j.pharmthera.2025.108824</a></p>2025-02-27T12:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.pharmthera.2025.108824https://figshare.com/articles/journal_contribution/GLP-1_receptor_agonists_are_we_witnessing_the_emergence_of_a_paradigm_shift_for_neuro-cardio-metabolic_disorders_/30455630CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304556302025-02-27T12:00:00Z |
| spellingShingle | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? Abdelilah Arredouani (10914455) Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences GLP-1 GLP-1 receptor GLP-1 receptor agonists Diabetes Obesity MASLD Neurodegenerative diseases |
| status_str | publishedVersion |
| title | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? |
| title_full | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? |
| title_fullStr | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? |
| title_full_unstemmed | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? |
| title_short | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? |
| title_sort | GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? |
| topic | Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Pharmacology and pharmaceutical sciences GLP-1 GLP-1 receptor GLP-1 receptor agonists Diabetes Obesity MASLD Neurodegenerative diseases |